A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis –The ASPEN Study

Project Details

StatusActive
Effective start/end date20/01/211/01/24

Funding

  • PPD PTY LTD: AUD23,350.00
  • PPD PTY LTD: AUD23,350.00